MADRIGAL PHARMACEUTICALS, INC.MDGLEarnings & Financial Report
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
MDGL Q4 2025 Key Financial Metrics
营收
$321.1M
毛利润
N/A
营业利润
$-59.6M
净利润
$-58.6M
毛利率
N/A
营业利润率
-18.6%
净利率
-18.2%
同比增长
210.8%
EPS
$-2.55
资金流向
MADRIGAL PHARMACEUTICALS, INC. Q4 2025 Financial Summary
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $321.1M (up 210.8% YoY) for Q4 2025, with a net profit of $-58.6M (up 1.4% YoY) (-18.2% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $321.1M |
|---|---|
| Net Profit | $-58.6M |
| Gross Margin | N/A |
| Operating Margin | -18.6% |
| Report Period | Q4 2025 |
Revenue Breakdown
MADRIGAL PHARMACEUTICALS, INC. Q4 2025 revenue of $321.1M breaks down across 3 segments, led by Rebates Customer Fees Credits Co Pay Assistance And Other at $208.5M (64.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 64.9% |
| Other | $76.0M | 23.7% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11.4% |
MADRIGAL PHARMACEUTICALS, INC. Annual Revenue by Year
MADRIGAL PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $958.4M). Click any linked year to see what changed vs the prior 10-K.
MADRIGAL PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
MADRIGAL PHARMACEUTICALS, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $321.1M | +210.8% | $-58.6M | -18.2% |
| Q3 2025 | $287.3M | +362.0% | $-114.2M | -39.8% |
| Q2 2025 | $212.8M | +1353.8% | $-42.3M | -19.9% |
| Q1 2025 | $137.3M | — | $-73.2M | -53.4% |
| Q4 2024 | $103.3M | — | $-59.4M | -57.5% |
| Q3 2024 | $62.2M | — | $-107.0M | -172.0% |
| Q2 2024 | $14.6M | — | $-152.0M | -1038.2% |
| Q1 2024 | $0 | — | $-147.5M | N/A |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $0 | $14.6M | $62.2M | $103.3M | $137.3M | $212.8M | $287.3M | $321.1M |
| 同比增长 | N/A | N/A | N/A | N/A | N/A | 1353.8% | 362.0% | 210.8% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.08B | $1.10B | $1.07B | $1.04B | $996.6M | $1.02B | $1.36B | $1.26B |
| 总负债 | $231.5M | $242.7M | $296.1M | $287.9M | $286.0M | $319.4M | $736.7M | $656.9M |
| 股东权益 | $850.8M | $857.1M | $777.2M | $754.4M | $710.6M | $696.0M | $625.7M | $602.7M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-149.2M | $-134.9M | $-67.0M | $-104.5M | $-88.9M | $-47.1M | $79.8M | $-133.5M |